Primary CNS Neuroblastoma, FOXR2 ‐Activated: Clinicopathological Study of Two Cases With Immunohistochemical Characterization and Literature Review
Neuropathology · 2026-04 · 46 (2)
DOI: 10.1111/neup.70049 ↗Kurz gefasst
Fallbericht in der Zeitschrift Neuropathology, online erschienen am 26.02.2026. Verfasst von Sumanta Das und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Agilus Diagnostic Ltd, Fortis Memorial Research Institute, Gurugram, Haryana, India. Hauptthemen laut MEDLINE: Brain Neoplasms, Forkhead Transcription Factors, Neuroblastoma. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
Primary central nervous system (CNS) neuroblastoma, FOXR2‐activated (CNS‐NB‐FOXR2), is a rare embryonal tumor characterized by neuroblastic differentiation and structural rearrangement of the FOXR2 gene. Previously grouped under CNS primitive neuroectodermal tumors (PNET), this entity has been reclassified based on genome‐wide DNA methylation profiling. In this study, we present the detailed clinicopathological and immunohistochemical features of two pediatric cases diagnosed at our center. The first case involved a six‐year‐old with a left frontal mass; the second was a one‐year‐old with a large bifrontal lesion. Radiologically, both cases mimicked other embryonal tumors or high‐grade gliomas. Histologically, tumors displayed small round blue cell morphology with neuroblastic features, including Homer‐Wright rosettes and ganglionic differentiation. Immunohistochemistry demonstrated diffuse positivity for OLIG2, synaptophysin, and L1CAM, with negative expression for GFAP, EMA, and IDH1 R132H. FOXR2 showed nuclear positivity in both cases, supporting the diagnosis. Both cases exhibited diffuse L1CAM positivity—a rare finding with limited evidence in the existing literature. Although DNA methylation profiling could not be performed, the diagnosis was supported by characteristic morphology and immunohistochemistry profile. This report highlights key diagnostic features and potential mimics of CNS neuroblastoma, FOXR2‐activated, and underscores the utility of immunohistochemistry in low‐resource settings. Recognizing this entity is essential for accurate classification and appropriate therapeutic planning. Further studies are warranted to explore targeted therapies, including MEK inhibitors, which may hold promise based on emerging molecular data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Agilus Diagnostic Ltd, Fortis Memorial Research Institute, Gurugram, Haryana, India.
- Department of Neurosurgery, Fortis Memorial Research Institute, Gurugram, Haryana, India.
- Department of Radiology, Fortis Memorial Research Institute, Gurugram, Haryana, India.
- Depertment of Medical Oncology, Fortis Memorial Research Institute, Gurugram, Haryana, India.
- Department of Neuropathology, Neuropathology Laboratory & Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, Delhi, India.
ORCID-Profile: Sumanta Das, Sunita Ahlawat, Suman S Karanth, Mehar Chand Sharma
Zitieren
APA
Das, S., Ahlawat, S., Agrawal, K., Shaikh, S., Gupta, R. K., Karanth, S. S., Vaishya, S., Patir, R., & Sharma, M. C. (2026). Primary CNS Neuroblastoma, FOXR2 ‐Activated: Clinicopathological Study of Two Cases With Immunohistochemical Characterization and Literature Review. Neuropathology, 46(2). https://doi.org/10.1111/neup.70049
Vancouver
Das S, Ahlawat S, Agrawal K, Shaikh S, Gupta RK, Karanth SS, et al. Primary CNS Neuroblastoma, FOXR2 ‐Activated: Clinicopathological Study of Two Cases With Immunohistochemical Characterization and Literature Review. Neuropathology. 2026;46(2). doi:10.1111/neup.70049
BibTeX
@article{Das2026,
author = {Das, Sumanta and Ahlawat, Sunita and Agrawal, Komal and Shaikh, Salman and Gupta, Rakesh Kumar and Karanth, Suman S and Vaishya, Sandeep and Patir, Rana and Sharma, Mehar Chand},
title = {Primary CNS Neuroblastoma, FOXR2 ‐Activated: Clinicopathological Study of Two Cases With Immunohistochemical Characterization and Literature Review},
journal = {Neuropathology},
year = {2026},
volume = {46},
number = {2},
doi = {10.1111/neup.70049}
}
EUVIMED